$2.82
-0.16 (-5.37%)
Open$2.97
Previous Close$2.98
Day High$3.01
Day Low$2.81
52W High$6.20
52W Low$1.31
Volume—
Avg Volume14.6K
Market Cap6.74M
P/E Ratio—
EPS$-2.29
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,355.0% upside
Current
$2.82
$2.82
Target
$41.03
$41.03
$36.60
$41.03 avg
$68.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.1K | 44.6K | 1.35M |
| Net Income | -6,154,786 | -18,911,940 | -84,207 |
| Profit Margin | -46,790.0% | -44,450.5% | -6.2% |
| EBITDA | -6,152,048 | -19,953,723 | -111,401 |
| Free Cash Flow | — | — | -113,905 |
| Rev Growth | -70.7% | -70.7% | +20.4% |
| Debt/Equity | — | — | 1.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |